{
    "clinical_study": {
        "@rank": "84057", 
        "arm_group": [
            {
                "arm_group_label": "Dose Escalation Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "AM0010 (1 ug/kg) - Daily subcutaneous (SC) injections of AM0010 for up to 4 cycles of 28 days"
            }, 
            {
                "arm_group_label": "Dose Escalation Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "AM0010 (2.5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days"
            }, 
            {
                "arm_group_label": "Dose Escalation Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "AM0010 (5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days"
            }, 
            {
                "arm_group_label": "Dose Escalation Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "AM0010 (10 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days"
            }, 
            {
                "arm_group_label": "Dose Escalation Cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "AM0010 (20 ug/kg) - Daily subcutaneous injections of AM0010 for up to 4 cycles of 28 days"
            }, 
            {
                "arm_group_label": "Dose Expansion Cohort", 
                "arm_group_type": "Experimental", 
                "description": "at least 15 patients will be dosed  with AM0010"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a first-in-human, open-label, dose escalation study to evaluate the safety and\n      tolerability of AM0010 in patients with advanced solid tumors, dosed daily subcutaneously."
        }, 
        "brief_title": "A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Melanoma", 
            "Prostate Cancer", 
            "Ovarian Cancer", 
            "Renal Cell Carcinoma", 
            "Colorectal Carcinoma", 
            "Pancreatic Carcinoma", 
            "Non-small Cell Lung Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Carcinoma, Renal Cell", 
                "Colorectal Neoplasms", 
                "Lung Neoplasms", 
                "Melanoma", 
                "Ovarian Neoplasms", 
                "Pancreatic Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced solid tumor, limited to melanoma, hormone refractory prostate cancer,\n             ovarian cancer,  renal cell carcinoma, colorectal carcinoma (CRC), pancreatic\n             carcinoma or non-small cell lung carcinoma (NSCLC) that is refractory to, intolerant\n             of, for which no standard of therapy is available or where the patient refuses\n             existing therapies\n\n          -  Measurable or evaluable disease according to irRC or bone metastatic disease\n             evaluable by Prostate Cancer Working Group 2 criteria (PCWG2) for\n             castration-resistant prostate cancer (CRPC)\n\n          -  At least 18 years of age\n\n          -  Performance Status of 0 or 1\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Hematologic malignancies\n\n          -  Pregnant or lactating\n\n          -  Present or history of neurological disorders such as Multiple Sclerosis and Guillain\n             Barre or inflammatory central nervous system/peripheral nervous system (CNS/PNS)\n             disorders\n\n          -  Myocardial infarction within the last 6 months\n\n          -  Unstable angina, or unstable cardiac arrhythmia requiring medication\n\n          -  Surgery within the last 28 days\n\n          -  Systemic fungal, bacterial, viral, or other infection\n\n          -  History of bleeding diathesis within the last 6 months\n\n          -  Positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009449", 
            "org_study_id": "AM0010-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose Escalation Cohort 1", 
                "Dose Escalation Cohort 2", 
                "Dose Escalation Cohort 3", 
                "Dose Escalation Cohort 4", 
                "Dose Escalation Cohort 5", 
                "Dose Expansion Cohort"
            ], 
            "description": "Daily subcutaneous injections of AM0010 up to 4 cycles of 28 days", 
            "intervention_name": "AM0010", 
            "intervention_type": "Drug", 
            "other_name": [
                "PEGylated recombinant human Interleukin-10", 
                "PEG-rHuIL-10"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Oncology", 
            "Cancer", 
            "Solid Tumors"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Caryn Kata", 
                    "phone": "617-582-7603"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patrick Ott, MD, Phd", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karen Autio, MD", 
                    "phone": "646-888-3359"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Karen Autio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "julie.pfrommer@scresearch.net", 
                    "last_name": "Julie Pfrommer Fey", 
                    "phone": "615-524-4110"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Infante, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "isabel.jimenez@start.stoh.com", 
                    "last_name": "Isabel Jimenez, RN, MSN", 
                    "phone": "210-593-5265"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "South Texas Accelerated Research Therapeutics"
                }, 
                "investigator": {
                    "last_name": "Kyrakos Papadopoulos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "ARMO", 
            "last_name": "Martin Oft, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability as measured by incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 4 months"
            }, 
            {
                "description": "PK parameters including the serum trough concentration (Minimal Drug Concentration (Cmin)), the maximal drug concentration (Cmax), area under the curve of serum concentration over time (Area Under the Curve/ AUC), and half-life (t\u00bd).", 
                "measure": "Pharmacokinetic (PK) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009449"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)", 
                "safety_issue": "No", 
                "time_frame": "approxinatetly 4 months"
            }, 
            {
                "measure": "Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)", 
                "safety_issue": "No", 
                "time_frame": "approximatley 4 months"
            }, 
            {
                "measure": "Anti-AM0010 antibody formation", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 4 months"
            }
        ], 
        "source": "ARMO BioSciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ARMO BioSciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}